TEST:

HepatoPredict

HepatoPredict was initially developed to select HCC patients for LT. We now show that using the same algorithm, the same biomarkers and clinical variables defined by radiology or histopathology can aid in the post-LT setting. HepatoPredict-mediated post-LT stratification can identify high-risk patients and improve the definition of more effective surveillance schemes and/or adjuvant therapies.

HepatoPredict was initially developed to select HCC patients for LT. We now show that using the same algorithm, the same biomarkers and clinical variables defined by radiology or histopathology can aid in the post-LT setting. HepatoPredict-mediated post-LT stratification can identify high-risk patients and improve the definition of more effective surveillance schemes and/or adjuvant therapies.

It can accurately identify HCC patients who are more likely to benefit from a LT. Its robust performance also confirms that it can be easily integrated into standard diagnostic laboratories.

"After a lot of under the hood work, we are happy to announce Version 2.0 of the HepatoPredict kit, more environmentally friendly, with improved stability and compatibility."

"Ophiomics is presenting further developments on HepatoPredict clinical validation at ILTS later this week. Joana Cardoso Vaz, our Chief Scientific Officer, will show initial data on intra-tumoral and inter-tumoral reproducibility of HepatoPredict with the title 'Testing HepatoPredict kit performance in liver transplantation prognosis for hepatocellular carcinoma when facing intra- and inter-tumoral heterogeneity' on Wednesday, May 3, 2023."

"Ophiomics secured a Series A investment round to support commercial development and continued technical/clinical development of its flagship product HepatoPredict, and to further support the development of a portfolio of products focused on early cancer detection and cancer patient stratification for treatment selection."

HepatoPredict outperforms conventional clinical-pathologic selection criteria, (Milan, UCSF) providing superior prognostic information. Accurately identifying which patients most likely benefit from LT enables an objective stratification of waiting lists and information-based allocation of optimal versus suboptimal organs.

"Biocartis Group NV...announces the start of the commercialization in Europe of the HepatoPredict test as a CE-IVD marked manual kit. The test, developed by Ophiomics, is a prognostic diagnostic test that supports the decision of liver transplantation in patients with Hepatocellular Carcinoma (HCC)."

"Ophiomics is attending ECP from 3-7 of September in Basel, Switzerland. We are be presenting HepatoPredict with our partner and distributor Biocartis. Come visit us at Biocartis Booth Nr 22."

"Our paper 'A gene expression signature to select hepatocellular carcinoma patients for liver transplantation' is finally out...This study published in Annals of Surgery is the first clinical validation of HepatoPredict, an algorithm combining biomarkers measured in liver tumor with clinical variables, to predict recurrence after liver transplantation."

"Another important step in the development of HepatoPredict and an occasion for celebration: HepatoPredict is now a registered medical device under the DIRECTIVE 98/79/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 October 1998 on in vitro diagnostic medical devices."

CONCLUSION HCC represents a unique challenging cancer requiring a multifactorial approach. The rapid development of molecular information-based diagnostic and therapeutic options will increasingly contribute to a personalized, “precision medicine” care of HCC patients.

"Biocartis Group NV...and Ophiomics...announce that they entered into a collaboration which will initially focus on the commercialization of HepatoPredict™, a prognostic gene expression signature test to help identify which patients will benefit from curative-intent surgery, in particular liver transplantation. HepatoPredict™ will be distributed by Biocartis in Europe as a manual kit mainly addressing centralized expert laboratories, and the test may later be translated into a version on Biocartis’ rapid and easy-to-use molecular diagnostics platform Idylla™...HepatoPredict™ will be launched as a CE-marked IVD manual kit in Q1 2022. The partnership will initially focus on Biocartis’ commercialization of the manual kit in Europe."